Tepotinib launch date in China

Tepotinib, marketed overseas under the English trade name Tepmetko, is a highly selective oralMET inhibitor, as ofOn December 8, 2023, according to information released by the National Medical Products Administration, the original drug has been approved in China through relevant regulations for the treatment of patients with non-small cell lung cancer (NSCLC) carrying MET exon 14 (METex14) skipping.

Tepotinib is the first oral MET inhibitor to receive regulatory approval anywhere in the world for the treatment of advanced non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations, and was approved in Japan in March 2020. The Phase II VISION trial is the largest study of a methionine inhibitor in this setting and was the basis for regulatory approval. The latest findings from the trial continue to show that METex14-skipped NSCLC patients treated with tepotinib had clinically meaningful long-term effects regardless of therapy (2L, 2L+, and 3L+).

Since the original drug Tepotinib has only been on the market for a short time in China, it is not yet eligible for medical insurance. Tepotinib Original drug currently marketed overseas is relatively expensive, and the price of each box of 225mg*30 tablets may be around RMB 80,000 (the price may fluctuate due to exchange rates). There are already generic Tepotinib drugs produced in other countries. The ingredients of these generic drugs are basically the same as those of the original drug, but the price is relatively cheap. For example, the price of 225mg*60 tablets produced by a Laos pharmaceutical factory may be more than 8,000 yuan per box (the price may fluctuate due to exchange rates).